Melatonin protects against methamphetamine-induced Alzheimer's disease-like pathological changes in rat hippocampus
- 1 September 2021
- journal article
- research article
- Published by Elsevier in Neurochemistry International
- Vol. 148, 105121
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- GSK-3 inhibition: Achieving moderate efficacy with high selectivityBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2013
- Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypesJournal of Clinical Investigation, 2012
- Is Cognitive Functioning Impaired in Methamphetamine Users? A Critical ReviewNeuropsychopharmacology, 2011
- Alzheimer’s Disease: The Challenge of the Second CenturyScience Translational Medicine, 2011
- Longitudinal assessment of Aβ and cognition in aging and Alzheimer diseaseAnnals of Neurology, 2011
- Methamphetamine toxicity and messengers of deathBrain Research Reviews, 2009
- An Akt/β-Arrestin 2/PP2A Signaling Complex Mediates Dopaminergic Neurotransmission and BehaviorCell, 2005
- Tau, tangles, and Alzheimer's diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2005
- Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levelsJournal of Pineal Research, 2003
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976